Inclusion Criteria:  Male or female patients aged ≥40 years old at study entry Patients diagnosed with COPD (based on post-bronchodilator forced expiratory volume 11/flow volume curve percent predicted forced (FEV1/FVC)<70% in the past and current or former smokers with a smoking history of ≥10 pack-years in the past) Patients who is on the new prescription of BGF pMDI 320/18/9.6µg twice daily as per the physician's decision, at baseline Patients with CAT≥10 at study entry Patients who are capable to fill PROs physically and/or mentally as judged by investigators Patients who provide written informed consent prior to the study entry  Exclusion Criteria:  Patients diagnosed as asthma by investigator's judgement at and/or before study entry Patients who participated in any interventional clinical studies and/or any relevant studies (quality of life (QoL) and respiratory researches) during the 12 weeks before the study entry and/or during this study Patients who used ICS+LABA+LAMA therapy including open triple and closed triple before the study entry Patients with history of exacerbation during 4 weeks before the study entry Patients with very severe comorbidities or status which would impact on QoL evaluation judged by investigators (e.g., heart failure, malignancy, receiving home oxygen therapy, pneumonia)